Key result
Bisoprolol, carvedilol, and metoprolol CR/XL similarly reduced mortality in systolic heart failure (relative risk reductions 34-42%), whereas nebivolol was less effective (16% reduction, NS).
Why the study?
Do different beta-blockers (bisoprolol, metoprolol CR/XL, carvedilol, nebivolol) have similar effects on mortality and tolerability in matched subsets of patients with systolic heart failure?
Do different beta-blockers (bisoprolol, metoprolol CR/XL, carvedilol, nebivolol) have similar effects on mortality and tolerability in matched subsets of patients with systolic heart failure?
Bisoprolol, carvedilol, and metoprolol CR/XL demonstrate similar efficacy and tolerability in systolic heart failure across varying NYHA classes and ejection fractions, whereas nebivolol appears less effective.
No takes yet. Share an insight, caveat, or question.
Supports preferring bisoprolol, carvedilol, or metoprolol CR/XL over nebivolol in systolic HF; confirms similar efficacy among the three in matched analyses.
Wikstrand et al. (2013) studied Systolic heart failure (n=10,077). Beta-blockers (bisoprolol, metoprolol CR/XL, carvedilol, nebivolol) vs. Placebo was evaluated on Annual mortality rates. Bisoprolol, carvedilol, and metoprolol CR/XL similarly reduced mortality in systolic heart failure (relative risk reductions 34-42%), whereas nebivolol was less effective (16% reduction, NS).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: